The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
France, March 27th, 2014 - Novasep, a leading supplier of manufacturing solutions to Life Science industries, today announces its unaudited consolidated results1 for the period ended December 31st, 2013.
Pompey, France, March 4, 2014 - Novasep, a leading provider of global manufacturing solutions for life science molecules and fine chemicals, today announces the appointment of Michel Spagnol as chairman of the Supervisory Board, following the departure of Roger-Marc Nicoud, the founder of the group. Novasep provides an update of its strategic projects.
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Pompey, France, 03 December 2013 - Novasep is proud to announce the launch of their new website in Chinese to better serve clients and partners in China. Novasep’s offering is particularly adapted to the specific market needs of this region, and this new website makes information more readily available to Chinese speakers.
This internal promotion strengthens the business unit and enhances the Executive Committee (COMEX).
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Pompey, France, 26 June 2013 - Novasep, a leading provider of purificationbased manufacturing solutions for life sciences molecules, today announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013. He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.